Pelubiprofen ( DrugBank: Pelubiprofen )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01781702 (ClinicalTrials.gov) | October 2010 | 30/1/2013 | Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients | A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients | Pelubiprofen;Celebrex;Rheumatoid Arthritis | Drug: Pelubiprofen 30 mg;Drug: Celebrex 200 mg | Daewon Pharmaceutical Co., Ltd. | NULL | Completed | 18 Years | 80 Years | Both | 120 | Phase 3 | NULL |